Adaptive Biotechnologies Corp’s recent filing unveils that its CEO and Chairman ROBINS CHAD M unloaded Company’s shares for reported $1.79 million on Feb 18 ’25. In the deal valued at $8.50 per share,211,160 shares were sold. As a result of this transaction, ROBINS CHAD M now holds 2,576,701 shares worth roughly $ 21.31 million.
Then, ROBINS CHAD M sold 158,921 shares, generating $1,344,472 in total proceeds. Upon selling the shares at $8.46, the CEO and Chairman now owns 2,576,701 shares.
Before that, ROBINS CHAD M sold 100,287 shares. Adaptive Biotechnologies Corp shares valued at $846,422 were divested by the CEO and Chairman at a price of $8.44 per share. As a result of the transaction, ROBINS CHAD M now holds 2,576,701 shares, worth roughly $21.31 million.
A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early January with a ‘”a Sector outperform”‘ rating. Piper Sandler also remained covering ADPT and has increased its forecast on December 21, 2022 with a “an Overweight” recommendation from previously “Neutral” rating. Credit Suisse started covering the stock on August 25, 2022. It rated ADPT as “an Underperform”.
Price Performance Review of ADPT
On Tuesday, Adaptive Biotechnologies Corp [NASDAQ:ADPT] saw its stock fall -0.72% to $8.27. Over the last five days, the stock has gained 7.68%. Adaptive Biotechnologies Corp shares have risen nearly 37.95% since the year began. Nevertheless, the stocks have risen 109.90% over the past one year. While a 52-week high of $8.74 was reached on 02/18/25, a 52-week low of $2.28 was recorded on 01/02/25. SMA at 50 days reached $7.03, while 200 days put it at $5.02.
Levels Of Support And Resistance For ADPT Stock
The 24-hour chart illustrates a support level at 7.92, which if violated will result in even more drops to 7.58. On the upside, there is a resistance level at 8.78. A further resistance level may holdings at 9.30. The Relative Strength Index (RSI) on the 14-day chart is 59.66, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.48, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 34.34%. Stochastics %K at 73.11% indicates the stock is a holding.
The most recent change occurred on June 03, 2022 when Piper Sandler began covering the stock and recommended ‘”a Neutral”‘ rating along with a $7.50 price target.
